API | tenofovir alafenamide

tenofovir alafenamide (genvoya) Report issue

Small molecule Approved ^FDA Fast Track ^FDA

AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW

Tenofovir alafenamide, sold under the brand name Vemlidy, is a hepatitis B virus (HBV) nucleotide reverse transcriptase inhibitor medication for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease. It is taken by mouth. ^Wikipedia

Chemistry

SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)Oc3ccccc3
InChIKey: LDEKQSIMHVQZJK-CAQYMETFSA-N
Mol. Mass: 476.47
ALogP: 2.97 Partition coefficient
ChEMBL Molecules:

tenofovir alafenamide

tenofovir alafenamide fumarate

More Chemistry

Pharmacology

Mechanism of Action:
- Reverse transcriptase/RNaseH (Human immunodeficiency virus 1) ^UniProt
Multi-specific: Missing data
Black Box: Yes
Availability: Prescription Only
Delivery Methods: Oral
Pro Drug: Yes

Drug Pricing (per unit)

United States

$27.6093 - $39.4336

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

biktarvy ( emtricitabine (emtriva), bictegravir (Biktarvy), tenofovir alafenamide (genvoya) )

descovy ( emtricitabine (emtriva), tenofovir alafenamide (genvoya) )

genvoya ( emtricitabine (emtriva), tenofovir alafenamide (genvoya), cobicistat (stribild), elvitegravir (vitekta) - other name: elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide )

odefsey ( emtricitabine (emtriva), tenofovir alafenamide (genvoya), rilpivirine (edurant) )

symtuza ( emtricitabine (emtriva), darunavir (prezista), tenofovir alafenamide (genvoya), cobicistat (stribild) )

Organizations (195)

Research & Development (191)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (7)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (56)

Approved Indications (1)

HIV Infections

Experimental Indications - Clinical Trial Phases 1-4 (56)

Alveolar Bone Loss (Phase 4)

Anesthesia and Analgesia (Early Phase 1)

Antiretroviral Therapy, Highly Active (Phase 4)

Art (Phase 4)

Arthritis (Phase 4)

Bone Diseases, Metabolic (Phase 4)

Buprenorphine (Phase 4)

Coinfection (Phase 4)

Coronary Artery Disease (Phase 4)

COVID-19 (Phase 3)

Drug Evaluation (Phase 4)

Drug Misuse (Phase 4)

Drugs, Investigational (Phase 4)

Fatigue (Phase 2)

Harm Reduction (Phase 4)

Health Personnel (Phase 3)

Healthy Volunteers (Phase 1)

Hepatitis B (Phase 4)

Hepatitis B, Chronic (Phase 4)

Hepatitis B virus (Phase 4)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 4)

Hepatitis D, Chronic (Phase 2)

Herpes Simplex (Phase 1)

HIV (Phase 4)

HIV-1 (Phase 4)

HIV Infections ()

HIV Seropositivity (Phase 3)

Hormones (Phase 4)

Immunosuppression Therapy (Phase 4)

Infectious Disease Transmission, Vertical (Phase 4)

Insulin Resistance (Phase 1)

Kidney Transplantation (Phase 4)

Leukemia, Lymphoid (Phase 2)

Liver Cirrhosis (Phase 4)

Liver Diseases (Phase 4)

Liver Failure (Phase 4)

Liver Transplantation (Phase 4)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Medication Adherence (Early Phase 1)

Menopause (Phase 4)

Methadone (Phase 4)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Neoplasms (Phase 3)

Opioid-Related Disorders (Phase 4)

Osteoporosis (Phase 4)

Pregnancy (Phase 2)

Renal Insufficiency (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Safety (Phase 4)

Sexually Transmitted Diseases (Phase 4)

Tenofovir (Phase 4)

Tuberculosis (Phase 4)

Tuberculosis, Pulmonary (Phase 2)

Virus Diseases (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 181
# of Trial Organizations: 191

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue